Investigation Report on China’s Paclitaxel Market 2021-2025

$2,600$3,900

In 2020, the hospital’s overall diagnosis and treatment services were impacted by the Covid-19 epidemic, and Paclitaxel was included in the second batch of national organization drug procurement due to more than 3 manufacturers.

Clear

Description

Description
Paclitaxel is a chemotherapeutic tumor drug used to treat metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months after adjuvant chemotherapy. Its product, developed by Abolis, was approved by the FDA in 2005 and was approved in China in 2008. By 2020, there are 34 manufacturers in the Chinese Paclitaxel market, with Nanjing Luye Pharmaceutical Co., Ltd. accounting for the most market share in the Chinese Paclitaxel market.

According to CRI analysis, the sales of Paclitaxel in the Chinese market increased year by year from 2016 to 2019. Among them, the annual growth rate of 40.86% was the highest in 2019, from CNY2.168 billion in 2018 to CNY3.053 billion in 2019. In 2020, the hospital’s overall diagnosis and treatment services were impacted by the Covid-19 epidemic, and Paclitaxel was included in the second batch of national organization drug procurement due to more than 3 manufacturers. With the sharp price reduction in centralized procurement, Paclitaxel sales have declined with a growth rate of -18.64%. The CAGR of Paclitaxel sales in the Chinese market from 2016 to 2020 was 7.16%.

CRI analyzes that the Pacilitaxel sales in China will increase steadily with the increase in breast cancer patients from 2021 to 2025. In 2020, the number of new cases of breast cancer worldwide reached 2.26 million, and breast cancer is the most commonly diagnosed cancer, overtaking lung cancer. Therefore, the sales and sales volume of Paclitaxel for the treatment of breast cancer will increase accordingly with the increase in the number of patients diagnosed. Furthermore, Paclitaxel will be included in the National Drug Price Negotiation in 2021, and then its sales will keep a continuous rise. In addition, the effective alleviation of the Covid-19 epidemic will lead to a recovery growth in the sales of Paclitaxel.

Topics Covered:
-The impact of COVID-19 on China’s Paclitaxel market
– Sales value of China’s Paclitaxel 2016-2020
– Competitive landscape of China’s Pacilitaxel market
– Prices of Paclitaxel in China
– Prices of Paclitaxel in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Paclitaxel market
– Prospect of China’s Paclitaxel market from 2021 to 2025

Additional information

Publisher

Geography Covered

Date Published

Pages

Charts

Format

Base Year

2016

Base Market Size

1883.65

Currency/Unit

CNY million

Forecast Year

2025

Market Size Forecast

4000.6

CAGR

8.73%

Table of Contents

Table of Contents

1 Relevant Concepts of Paclitaxel

1.1 Indications for Paclitaxel

1.2 Development of Paclitaxel in China

1.3 Governmental Approval of Paclitaxel in China

1.4 The Impact of COVID-19 on Paclitaxel sales in China

 

2 Sales of Paclitaxel in China, 2016-2020

2.1 Sales Value of Paclitaxel

2.1.1 Overall Sales Value

2.1.2 Sales Value by Regions

2.2 Sales Volume of Paclitaxel

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Regions

2.3 Sales of Paclitaxel by Dosage Form in China, 2016-2020

2.3.1 Liposome injection

2.3.2 Injection (nanoparticle albumin-bound)

2.3.3 Injection

2.3.4 Analysis of Other Dosage Forms

 

3 Analysis of Major Paclitaxel Manufacturers in China, 2016-2020

3.1 Analysis of Market Share of Major Paclitaxel Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Nanjing Luye Pharmaceutical Co., Ltd.

3.2.1 Enterprise Profile

3.2.2 Sales of LIPOSOME (Nanjing Luye Pharmaceutical Co., Ltd.’s Paclitaxel) in China

3.3  CSPC Ouyi Pharmaceutical Group Co., Ltd.

3.3.1 Enterprise Profile

3.3.2 Sales of Keaili (CSPC Ouyi Pharmaceutical Group Co., Ltd.’s Paclitaxel) in China

3.4 Jiangsu Hengrui Pharmaceutical Co., Ltd.

3.4.1 Enterprise Profile

3.4.2 Sales of Aiyue (Jiangsu Hengrui Pharmaceutical Co., Ltd.’s Paclitaxel) in China

3.5 Hospira Australia Pty Ltd

3.5.1 Enterprise Profile

3.5.2 Sales of Paclitaxel (Hospira Australia Pty Ltd’s Paclitaxel) in China

3.6 Beistol-Myers Squibb S.r.l.

3.6.1 Enterprise Profile

3.6.2 Sales of TAXOL (Beistol-Myers Squibb S.r.l.’s Paclitaxel) in China

 

4 Prices of Paclitaxel for Different Manufacturers in China, 2020-2021

4.1 Nanjing Luye Pharmaceutical Co., Ltd. (LIPOSOME)

4.2 CSPC Ouyi Pharmaceutical Group Co., Ltd. (Keaili)

4.3 Jiangsu Hengrui Pharmaceutical Co., Ltd. (Aiyue)

4.4 Hospira Australia Pty Ltd (ANZATAX)

4.5 Beistol-Myers Squibb S.r.l.(TAXOL)

 

5 Prospect of Chinese Paclitaxel Market, 2021-2025

5.1 Influential Factors of Chinese Paclitaxel Market Development

5.1.1 The Impact of COVID-19 on Chinese Paclitaxel Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

 

List of Charts

Chart Patent Information About Paclitaxel Liposome Injection Registration in China

Chart Patent Information About Paclitaxel (Nanoparticle Albumin-bound) Injection Registration in China

Chart Patent Information About Paclitaxel Injection Registration in China

Chart Sales Value of Paclitaxel Liposome Injection over the World

Chart Sales Value of Paclitaxel Injection (Nanoparticle Albumin-bound) over the World

Chart Sales Value of Paclitaxel Injection over the World

Chart Sales Value of Paclitaxel Liposome Injection in China, 2016-2020

Chart Sales Value of Paclitaxel Injection (Nanoparticle Albumin-bound) in China, 2016-2020

Chart Sales Value of Paclitaxel Injection in China, 2016-2020

Chart Sales Value of Paclitaxel Liposome Injection in China by Regions, 2016-2020

Chart Sales Value of Paclitaxel Injection (Nanoparticle Albumin-bound) in China by Regions, 2016-2020

Chart Sales Value of Paclitaxel Injection in China by Regions, 2016-2020

Chart Sales Volume of Paclitaxel Liposome Injection in China, 2016-2020

Chart Sales Volume of Paclitaxel Injection (Nanoparticle Albumin-bound) in China, 2016-2020

Chart Sales Volume of Paclitaxel Injection in China, 2016-2020

Chart Sales Volume of Paclitaxel Liposome Injection in China by Regions, 2016-2020

Chart Sales Volume of Paclitaxel Injection (Nanoparticle Albumin-bound) in China by Regions, 2016-2020

Chart Sales Volume of Paclitaxel Injection in China by Regions, 2016-2020

Chart Market Share by Sales Value of Top Paclitaxel Manufacturers in China, 2016-2020

Chart Market Share by Sales Value of Top Paclitaxel Manufacturers in China, 2016-2020

Chart Market Share by Sales Value of Top Injection Manufacturers in China, 2016-2020

Chart Sales Value and Volume of LIPOSOME in China, 2016-2020

Chart Sales Value and Volume of Keaili in China, 2016-2020

Chart Sales Value and Volume of Aiyue in China, 2016-2020

Chart Sales Value and Volume of ANZATAX in China, 2016-2020

Chart Sales Value and Volume of TAXOL in China, 2016-2020

Chart Referential Prices of LIPOSOME in China by Regions, 2020-2021

Chart Referential Prices of Keaili in China by Regions, 2020-2021

Chart Referential Prices of Aiyue in China by Regions, 2020-2021

Chart Referential Prices of ANZATAX in China by Regions, 2020-2021

Chart Referential Prices of TAXOL in China by Regions, 2020-2021

Chart Forecast on Sales Value of Liposome Injection in China, 2021-2025

Chart Forecast on Sales Value of Injection (Nanoparticle Albumin-bound) in China, 2021-2025

Chart Forecast on Sales Value of Injection in China, 2021-2025

Chart Forecast on Sales Volume of Liposome Injection in China, 2021-2025

Chart Forecast on Sales Volume of Injection (Nanoparticle Albumin-bound) in China, 2021-2025

Chart Forecast on Sales Volume of Injection in China, 2021-2025